Lei Chen
Founder
Rarity Bioscience
Rarity Bioscience offers superRCA®, an ultrasensitive multiplex assay that detects rare nucleic acid sequences in liquid biopsy and tissue samples, achieving sensitivity levels of one mutation in 100,000. This technology enables precise identification of cancer mutations, enhancing the diagnostic capabilities of liquid biopsies and facilitating faster, cost-effective testing through established flow cytometry methods.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$536.5KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current methods for detecting rare mutations in liquid biopsies and tissue samples often lack the sensitivity needed for early and accurate diagnosis of diseases like cancer. Traditional assays may miss critical mutations present at very low frequencies, leading to delayed or inaccurate diagnoses.
Solution
Rarity Bioscience offers superRCA®, an ultrasensitive molecular amplification technology designed to detect rare nucleic acid sequences in liquid biopsy and tissue samples. The superRCA® assays achieve a sensitivity level of one mutation in 100,000 wild-type sequences, enabling precise identification of low-abundance mutations. By utilizing established flow cytometry methods for read-out, superRCA® facilitates faster and more cost-effective testing, making high-sensitivity mutation detection more accessible to laboratories and researchers. The technology enhances the diagnostic capabilities of liquid biopsies and supports applications such as minimal residual disease (MRD) monitoring and clinical trials.
Target Audience
The primary target audience includes clinical laboratories, research institutions, and pharmaceutical companies involved in cancer diagnostics, minimal residual disease monitoring, and clinical trials.
Features
- Ultrasensitive detection of rare mutations with a limit of detection down to 0.001% mutant allele frequency (MAF)
- Multiplexing capability to analyze up to 100 targets from a single DNA sample
- Utilizes standard flow cytometry for rapid and cost-efficient read-out
- Compatible with both liquid biopsy and tissue samples
- Available as standard kits, on-demand products, and service testing
- Demonstrated precision with CV ≤ 12% at 0.05% MAF
- Detects multiple mutations in exon 12 of NPM1, including MutA, MutB, and MutD